Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

To determine the accuracy of NIR/US assessment of tumor vasculature and oxygen changes in predicting and monitoring early neoadjuvant treatment response compared to pathological response.

Inclusion Criteria:

• Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2- breast cancer (for the endocrine therapy cohort)
• At least 18 years of age
• Female
• Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion Criteria:

• Pregnant and/or breastfeeding
• Prior history of breast cancer
• Prior history of chest wall radiation
• Prior history of breast reconstruction, reduction, or augmentation